porcin
reproduct
respiratori
syndrom
viru
prrsv
caus
agent
one
devast
econom
signific
viral
diseas
pig
worldwid
vaccin
current
avail
market
elicit
limit
protect
recombin
vesicular
stomat
viru
vsv
replicon
particl
vrp
use
success
induc
protect
influenza
viru
iav
chicken
bluetongu
viru
sheep
studi
vsv
vrp
express
prrsv
envelop
protein
nucleocapsid
protein
n
individu
combin
gener
evalu
potenti
vector
vaccin
prrsv
infect
high
level
express
recombin
prrsv
protein
demonstr
cell
cultur
howev
none
prrsv
antigen
express
vrp
except
n
protein
induc
detect
antibodi
respons
pig
challeng
infect
prrsv
challeng
howev
antibodi
respons
appear
averag
week
earlier
pig
vaccin
empti
control
vrp
reduct
viremia
observ
vaccin
group
compar
control
group
pig
covaccin
vrp
express
iav
antigen
vrp
express
prrsv
glycoprotein
antibodi
respons
iav
antigen
detect
data
show
vsv
replicon
vector
induc
immun
respons
heterolog
protein
pig
prrsv
envelop
protein
express
vsv
vrp
poorli
immunogen
nevertheless
prime
immun
system
significantli
earlier
bcell
respons
follow
prrsv
challeng
infect
infect
porcin
reproduct
respiratori
syndrom
viru
prrsv
caus
reproduct
failur
sow
respiratori
disord
particularli
young
pig
result
import
econom
loss
worldwid
recent
highli
pathogen
prrsv
strain
emerg
china
eastern
europ
prrsv
envelop
posit
sens
singlestrand
rna
viru
belong
famili
arterivirida
within
order
nidoviral
two
prrsv
genotyp
distinguish
type
prrsv
european
origin
type
prrsv
origin
north
america
china
spread
worldwid
high
genet
antigen
divers
prrsv
genom
consist
least
open
read
frame
orf
orf
encod
nonstructur
protein
two
polyprotein
process
proteolyt
well
two
protein
result
ribosom
frameshift
within
gene
detail
review
see
remain
orf
encod
structur
protein
subgenom
messeng
rna
orf
encod
glycoprotein
also
term
nonglycosyl
protein
also
term
e
glycoprotein
nonglycosyl
membran
protein
open
access
correspond
nicolasruggli
iviadminch
institut
virolog
immunolog
ivi
sensemattstrass
switzerland
full
list
author
inform
avail
end
articl
nucleocapsid
protein
n
respect
review
recent
altern
protein
identifi
minor
compon
equin
arter
viru
eav
prrsv
virion
form
disulphidelink
heterodim
essenti
format
infecti
particl
eav
glycoprotein
form
heterotrimer
complex
stabilis
disulphid
bond
demonstr
prrsv
yet
review
prrsv
complex
link
essenti
noncoval
interact
basic
protein
n
associ
viral
rna
genom
form
nucleocapsid
n
immunogen
prrsv
structur
protein
elicit
strong
antibodi
respons
day
post
infect
pi
antibodi
howev
neutral
viru
therefor
protect
major
neutral
epitop
found
also
divers
structur
protein
isol
neutral
epitop
also
found
contribut
protect
unclear
coexpress
elicit
better
neutral
ab
respons
alon
howev
neutral
antibodi
appear
typic
sever
week
onset
first
antibodi
respons
simultan
clearanc
viru
bloodstream
develop
vaccin
prrsv
partial
success
far
remain
challeng
task
comprehens
review
see
current
two
type
prrsv
vaccin
market
modifi
liveviru
vaccin
mlv
inactiv
vaccin
mlv
typic
efficaci
inactiv
vaccin
numer
altern
prrsv
vaccin
approach
explor
limit
success
far
review
effort
includ
instanc
dna
vaccin
subunit
peptid
vaccin
viral
vector
vaccin
plantderiv
vaccin
propagationincompet
recombin
vesicular
stomat
viru
vsv
repres
yet
anoth
vector
vaccin
approach
recombin
vsv
replicon
lack
vsv
glycoprotein
g
gene
carri
gene
interest
instead
packag
viru
replicon
particl
vrp
high
infecti
titr
use
complement
gexpress
cell
line
vrp
use
success
past
induc
protect
sar
coronaviru
mous
model
influenza
viru
iav
chicken
mice
bluetongu
viru
btv
sheep
vsv
vrp
safe
due
lack
glycoprotein
g
express
prevent
assembl
spread
viru
particl
pig
typic
preexist
immun
vsv
thu
vsv
replicon
repres
attract
novel
vaccin
platform
pig
howev
evalu
pig
yet
present
studi
vsv
vrp
gener
express
differ
combin
major
minor
prrsv
glycoprotein
immunogen
protect
potenti
vrp
assess
pig
cell
atcc
lgc
standard
grown
dulbecco
modifi
eagl
medium
dmem
life
technolog
supplement
foetal
bovin
serum
fb
biowest
cell
obtain
german
cell
cultur
collect
dszm
grown
earl
minim
essenti
medium
eagl
mem
life
technolog
supplement
fb
transgen
cell
clone
express
vsv
g
protein
regul
manner
maintain
describ
previous
type
prrsv
strain
kindli
provid
lui
enjuan
centro
nacion
de
madrid
spain
viru
variant
origin
viru
therefor
propag
titrat
cell
detect
prrsv
protein
monoclon
antibodi
mab
direct
prrsv
n
mab
direct
amino
acid
prrsv
kindli
provid
han
nauwynck
univers
ghent
belgium
polyclon
rabbit
serum
prrsv
obtain
lui
enjuan
centro
nacion
de
madrid
spain
serum
gener
biogen
germani
purifi
recombin
prrsv
express
baculoviru
system
mab
direct
prrsv
mab
prrsv
gift
ingenasa
madrid
spain
rabbit
antimyc
antiserum
mous
antiflag
antibodi
mab
purchas
sigmaaldrich
mous
antiha
antibodi
roch
secondari
antibodi
goat
antimous
igg
alexa
goat
antirabbit
igg
alexa
molecular
probe
antiswin
igg
antibodi
conjug
rhodamin
purchas
rockland
polyclon
rabbit
antimous
igg
coupl
horseradish
peroxidas
dako
cdna
codonoptim
cdna
prrsv
strain
genbank
access
number
deriv
respect
kindli
provid
lui
enjuan
centro
nacion
de
madrid
spain
codonoptim
cdna
n
strain
genbank
access
number
synthes
genscript
piscataway
gener
recombin
vsv
replicon
n
insert
plasmid
pvsv
use
mlui
bsteii
restrict
site
upstream
downstream
fourth
transcript
unit
replac
g
gene
vsv
analog
previou
report
replicon
contain
addit
transcript
unit
posit
express
green
fluoresc
protein
gfp
refer
asterisk
vector
nomenclatur
result
plasmid
design
pvsv
pvsv
n
respect
gener
dual
antigen
express
vector
cdna
insert
pvsv
use
xhoi
nhei
restrict
site
therebi
replac
gfp
gene
fifth
transcript
unit
result
plasmid
design
gener
tripl
antigen
express
vector
cdna
insert
vector
contain
transcript
unit
describ
recent
use
mlui
case
xhoi
case
nhei
case
restrict
site
result
plasmid
design
express
modifi
contain
short
peptid
epitop
c
terminu
gene
respect
insert
without
stop
codon
plasmid
vector
agil
technolog
upstream
frame
tripl
flag
epitop
dykddddk
code
region
follow
stop
codon
mflag
open
read
frame
amplifi
pcr
insert
fourth
transcript
unit
pvsv
result
plasmid
pvsv
mflag
pvsv
respect
antigen
modifi
fuse
short
ha
epitop
ypydvpdya
c
terminu
modifi
c
terminu
short
myc
epitop
eqkliseedl
orf
insert
fourth
transcript
unit
pvsv
result
plasmid
pvsv
pvsv
pvsv
respect
express
ectodomain
without
ctermin
transmembran
domain
gene
cassett
encod
amino
acid
number
accord
genbank
access
number
insert
frame
leader
sequenc
optim
signalas
cleavag
site
mammalian
express
vector
invitrogen
way
fuse
myc
peptid
epitop
histidin
tag
c
terminu
follow
stop
codon
construct
amplifi
pcr
insert
fourth
transcript
unit
pvsv
result
plasmid
pvsv
express
iav
protein
cdna
encod
ha
na
np
iav
kindli
provid
olga
stech
friedrichloefflerinstitut
greifswaldinsel
riem
germani
gene
insert
plasmid
pvsv
use
mlui
bsteii
restrict
site
replac
g
gene
vsv
describ
nucleotid
sequenc
confirm
sanger
sequenc
recombin
replicon
propag
helper
cell
line
provid
vsv
g
protein
tran
yield
infecti
vrp
titr
infecti
unit
iu
ml
describ
previous
titrat
gfp
express
use
readout
detect
vrp
express
gfp
infect
cell
fix
pb
contain
paraformaldehyd
pfa
min
wash
pb
contain
wv
glycin
permeabil
vv
triton
cell
incub
rabbit
antivsv
serum
subsequ
goat
antirabbit
horseradish
peroxidas
conjug
dako
stain
aec
h
substrat
overview
construct
vsv
vrp
provid
tabl
cell
grown
cover
slip
inocul
min
recombin
vrp
use
multipl
infect
moi
iucel
h
post
infect
cell
fix
pfa
min
wash
pb
contain
wv
glycin
cell
permeabil
vv
triton
min
subsequ
incub
primari
secondari
antibodi
dilut
pb
contain
bovin
serum
albumin
bsa
incub
period
min
room
temperatur
cell
wash
three
time
pb
final
cell
wash
distil
water
embed
mowiol
mount
medium
sigmaaldrich
pig
obtain
specif
pathogen
free
spf
breed
facil
institut
virolog
immunolog
ivi
three
experi
perform
experi
pig
randomli
assign
treatment
group
hous
separ
stabl
group
immun
intramuscular
inject
ml
cell
cultur
supernat
contain
iuml
recombin
vrp
first
experi
group
pig
n
immun
three
time
week
age
control
vsv
vrp
respect
second
experi
one
group
pig
n
immun
twice
week
age
mixtur
second
group
n
receiv
control
vsv
vrp
third
experi
group
pig
n
immun
three
time
month
age
two
differ
vsv
vrp
inject
two
differ
site
ie
vsv
n
vsv
ha
belz
vsv
vsv
belz
vsv
vsv
na
belz
vsv
control
vsv
np
belz
respect
experi
pig
challeng
via
intranas
rout
tcid
anim
prrsv
strain
week
last
vaccin
challeng
viru
dilut
ml
mem
administ
dropwis
intranas
blood
taken
vaccin
regular
interv
vaccin
challeng
infect
serum
store
bodi
temperatur
clinic
score
monitor
daili
accord
defin
score
system
experi
pig
perform
complianc
swiss
anim
protect
law
approv
anim
welfar
committe
canton
bern
switzerland
author
number
titrat
end
point
dilut
perform
cell
grown
plate
cell
inocul
tenfold
serial
dilut
serum
sampl
h
pi
cell
fix
immunoperoxidas
stain
antin
mab
perform
accord
standard
protocol
end
point
titr
express
tissu
cultur
infecti
dose
tcid
ml
limit
detect
log
tcid
ml
total
cellular
rna
extract
pig
sera
use
nucleospin
multi
viru
kit
machereynagel
freedom
evo
robot
tecan
store
detect
viral
rna
revers
transcriptas
quantit
pcr
rtqpcr
base
amplif
conserv
region
perform
duplic
employ
gfp
messeng
rna
intern
control
result
express
total
number
cycl
minu
quantif
cycl
cq
valu
elisa
prr
idexx
laboratori
use
measur
antiprrsv
igg
antibodi
sampl
posit
sp
ratio
higher
consid
posit
antibodi
prrsv
detect
use
hous
competit
indirect
elisa
ingenasa
madrid
spain
elisa
perform
plate
coat
recombin
antigen
prrsv
elisa
percentag
competit
calcul
use
formula
odneg
odsampl
odneg
odpo
posit
neg
control
provid
ingenasa
spain
sampl
consid
posit
percentag
competit
indirect
elisa
appropri
cutoff
set
detect
creactiv
protein
crp
genway
haptoglobin
hp
genway
mabtech
pig
sera
commerci
avail
elisa
use
accord
manufactur
protocol
porcin
determin
elisa
describ
previous
serum
sampl
heat
inactiv
min
prior
perform
serum
neutral
assay
twofold
serial
dilut
sera
mix
equal
volum
tcid
prrsv
incub
tissu
cultur
plate
h
h
cell
ad
well
day
cultur
plate
fix
pfa
presenc
viru
detect
cpe
stain
antin
mab
aech
viru
neutral
titr
express
reciproc
serum
dilut
lead
reduct
infect
data
analys
graphpad
prism
softwar
signific
differ
group
assess
multipl
test
p
consid
signific
previou
work
propagationincompet
vsv
replicon
vector
gener
replac
gene
glycoprotein
g
fourth
transcript
unit
viral
genom
influenza
viru
gene
replicon
contain
gfp
gene
refer
asterisk
vector
nomenclatur
addit
transcript
unit
posit
base
vector
gener
sever
vsv
vrp
express
individu
structur
antigen
prrsv
combin
thereof
evalu
prr
vaccin
candid
see
materi
method
tabl
empti
parent
vsv
vector
serv
control
vsv
vrpmediat
express
recombin
prrsv
antigen
studi
cell
take
advantag
broad
tropism
vsv
particl
allow
direct
comparison
recombi
cell
infect
either
vsv
react
specif
mab
cell
infect
either
vsv
react
polyclon
immun
serum
figur
sinc
specif
antibodi
avail
express
could
demonstr
tag
omit
purpos
preserv
natur
conform
three
protein
nevertheless
myctag
express
detect
vsv
use
antimyc
serum
shown
aim
evalu
whether
protein
secret
supernat
may
enhanc
bcell
respons
vsv
replicon
construct
express
ectodomain
fuse
leader
sequenc
optim
signalas
cleavag
site
myctag
ectodomain
react
mab
antimyc
serum
expect
figur
westernblot
analysi
antimyc
serum
demonstr
presenc
kda
protein
cell
lysat
ly
howev
miss
supernat
sn
vsv
infect
cell
figur
show
ectodomain
retain
intracellular
compart
despit
signal
sequenc
lack
transmembran
domain
final
express
prrsv
n
antigen
vsv
n
demonstr
immunofluoresc
figur
western
blot
figur
use
antin
mab
kda
protein
detect
lysat
vsv
n
prrsv
cell
complex
constitut
major
protein
compon
prrsv
envelop
neutral
antibodi
form
therefor
first
determin
immunogen
vsv
replicon
pig
two
group
five
pig
immun
three
time
control
vsv
respect
challeng
week
later
homolog
prrsv
strain
follow
fever
day
pi
wherea
control
pig
fever
despit
slightli
elev
bodi
temperatur
figur
b
anim
develop
low
viremia
short
durat
figur
maximum
mean
viru
titr
log
tcid
ml
reach
serum
day
post
challeng
viru
detect
day
viral
rna
day
challeng
signific
differ
viremia
viral
rna
serum
observ
vaccin
group
control
group
time
challeng
infect
vaccin
induc
detect
antibodi
respons
measur
elisa
shown
first
antibodi
respons
detect
elisa
vaccin
group
five
pig
day
challeng
pig
group
posit
day
pi
pig
vsv
control
group
remain
antibodi
neg
time
tabl
vsv
control
group
antibodi
detect
first
time
day
pi
pig
seroconvers
n
respons
prrsv
challeng
infect
similar
two
group
first
nspecif
seroconvers
observ
day
pi
tabl
viru
neutral
antibodi
detect
anim
neither
challeng
day
day
pi
could
detect
serum
time
data
shown
specif
tcell
respons
detect
challeng
shown
therefor
investig
acut
phase
protein
crp
hp
earli
sensit
marker
diseas
inflamm
includ
prrsv
infect
increas
group
day
pi
figur
f
howev
signific
differ
could
detect
vaccin
control
anim
time
thu
apart
prime
pig
antibodi
respons
challeng
infect
vector
could
induc
seroconvers
challeng
sign
protect
viremia
infect
order
determin
whether
immun
respons
could
enhanc
induc
challeng
provid
three
minor
glycoprotein
togeth
pig
n
immun
twice
mixtur
vsv
control
n
follow
prrsv
challeng
day
challeng
two
four
vaccin
pig
develop
mild
fever
figur
control
anim
remain
free
fever
figur
anim
develop
short
viremia
follow
challeng
infect
signific
differ
viral
rna
load
viru
titr
vaccin
control
group
figur
previou
experi
maximum
mean
viru
titr
log
tcid
ml
reach
day
post
challeng
challeng
infect
vaccin
vrp
express
structur
protein
prrsv
induc
detect
antibodi
respons
measur
elisa
shown
follow
challeng
infect
antibodi
respons
detect
day
pi
pig
pig
vaccin
vrp
express
prrsv
protein
seroconvert
day
pi
tabl
pig
vsv
control
group
remain
neg
day
pi
seroconvers
tabl
vsv
control
group
remain
neg
day
pi
immun
respons
could
detect
vaccin
anim
day
pi
also
seroconvers
n
follow
challeng
similar
two
group
tabl
none
anim
develop
neutral
antibodi
challeng
day
day
pi
found
sera
experi
either
data
shown
wherea
serum
crp
hp
level
increas
significantli
group
day
challeng
declin
subsequ
day
pi
crp
hp
level
significantli
differ
vaccin
control
group
figur
f
suggest
vaccin
group
develop
slightli
reduc
inflammatori
respons
covaccin
togeth
two
vaccin
trial
show
vsv
vrp
induc
detect
seroconvers
prrsv
challeng
protect
viru
infect
viremia
nevertheless
vector
clearli
prime
pig
earlier
prrsvspecif
antibodi
respons
challeng
infect
poor
immunogen
vsv
vrp
express
prrsv
envelop
protein
contrast
previou
report
show
protect
iav
btv
infect
chicken
sheep
respect
thu
lack
antibodi
induct
immun
pig
vrp
express
five
prrsv
envelop
protein
rais
question
whether
vector
vaccin
suitabl
induct
antibodi
respons
pig
whether
prrsv
protein
poorli
immunogen
per
se
order
test
immunogen
prrsv
iav
protein
express
vsv
vrp
assess
anim
covaccin
two
differ
vsv
vrp
construct
express
prrsv
protein
n
empti
vector
iav
protein
ha
na
np
respect
inject
two
differ
site
see
materi
method
vaccin
pig
challeng
homolog
prrsv
strain
antibodi
respons
detect
influenza
viru
protein
day
vaccin
includ
neutral
antibodi
shown
seroconvers
prrsv
protein
except
n
could
detect
challeng
tabl
pig
vaccin
vsv
n
seroconvert
day
vaccin
day
third
vaccin
follow
challeng
infect
prrsv
control
group
seroconvert
day
pi
evid
protect
viru
infect
prrsv
challeng
indic
kinet
viremia
data
shown
nevertheless
immun
respons
induc
earlier
challeng
day
pi
vsv
vaccin
pig
compar
vsv
pig
respons
day
pi
immun
respons
also
induc
day
pi
wherea
vsv
pig
stay
seroneg
line
two
previou
immun
trial
data
show
prime
effect
importantli
howev
simultan
vaccin
pig
two
differ
vrp
show
clearli
prrsv
antigen
far
less
immunogen
iav
antigen
test
current
prrsv
vaccin
market
limit
efficaci
come
sever
drawback
avoid
biolog
risk
viru
spread
circumv
potenti
immun
modul
properti
modifi
live
prrsv
vaccin
therefor
explor
immunogen
protect
potenti
vsv
replicon
particl
vector
vaccin
approach
prrsv
vrp
success
use
efficaci
experiment
vaccin
sar
iav
btv
present
studi
vsv
replicon
engin
express
prrsv
structur
protein
individu
combin
tabl
emphasi
sinc
protein
import
target
neutral
protect
antibodi
major
neutral
epitop
resid
sinc
sever
studi
shown
coexpress
prrsv
antigen
result
better
humor
cellular
immun
respons
express
individu
protein
protein
coexpress
partli
mimic
format
oligom
vaccin
pig
vrp
express
two
five
prrsv
envelop
protein
total
result
signific
reduct
viremia
compar
control
group
tendenc
reduc
prrsvrelat
inflammatori
respons
observ
five
protein
express
interestingli
vaccin
induc
fever
day
follow
challeng
infect
prrsv
wherea
mockvaccin
pig
remain
asymptomat
fever
less
pronounc
envelop
protein
includ
vaccin
enhanc
diseas
follow
vaccin
recombin
observ
previous
attribut
antibodydepend
enhanc
diseas
natur
infect
probabl
mediat
nonneutr
antibodi
antibodi
shown
increas
viru
infect
porcin
alveolar
macrophag
cultur
vivo
involv
differ
isoform
neutral
antibodi
found
time
follow
vaccin
challeng
infect
nevertheless
vaccin
pig
seroconvert
day
earlier
mockvaccin
anim
challeng
viru
infect
indic
immun
recombin
vrp
prime
immun
system
pig
delay
seroconvers
envelop
protein
oppos
n
protein
prrsv
infect
immun
vector
vaccin
well
tabl
document
note
viru
use
studi
seroconvers
n
becam
detect
day
challeng
tabl
oppos
report
occurr
antin
antibodi
earli
day
prrsv
infect
probabl
relat
low
level
short
durat
replic
viru
pig
figur
despit
poor
replic
viru
vivo
vaccin
pig
vrp
result
signific
reduct
viremia
better
immunogen
prrsv
protein
report
antigen
modifi
coupl
immunostimulatori
molecul
administ
purifi
protein
along
adjuv
rais
question
whether
immunogen
prrsv
envelop
protein
express
vrp
affect
glycosyl
subcellular
local
intracellular
retent
low
stabil
order
elabor
modifi
aim
obtain
secret
replac
leader
sequenc
canon
signal
sequenc
follow
optim
signalas
cleavag
site
delet
hydrophob
transmembran
anchor
howev
modifi
retain
cell
seroconvers
obtain
absenc
challeng
viru
infect
lack
secret
may
relat
fact
natur
retain
intracellular
compart
despit
ntermin
signal
sequenc
order
address
question
whether
prrsv
structur
protein
immunogen
express
vsv
vrp
pig
vector
express
prrsv
n
protein
includ
one
vaccin
trial
n
chosen
immunogen
structur
protein
prrsv
infect
inde
vsv
n
vrp
capabl
induc
detect
antibodi
respons
absenc
viral
challeng
tabl
covaccin
experi
vrp
express
iav
prrsv
envelop
protein
corrobor
result
iav
protein
strongli
immunogen
prrsv
envelop
protein
clearli
demonstr
vsv
vector
per
se
function
pig
although
sever
vector
vaccin
fail
induc
protect
immun
respons
immun
essenti
prime
immun
system
challeng
infect
report
present
studi
altogeth
suggest
prrsv
envelop
protein
express
way
hide
partial
immun
system
whether
immun
evas
strategi
due
sole
glycan
shield
particular
intracellular
topolog
remain
investig
futur
effort
vector
vaccin
develop
consid
aspect
enhanc
immunogen
prrsv
antigen
accept
presubmiss
inquiri
selector
tool
help
find
relev
journal
